Document Classification

Section Type: RESULTS

Text: Ezetimibe treatment for 4 weeks significantly suppressed postprandial elevation in TG (area under the incremental curve, from 1419594 to 96832 1 mg h/dl, P < 0. 05), remnant lipoprotein cholesterol (from 66. 927. 6 to 38. 915. 4 mg h/dl, P < 0. 01) and apoB-48 (from 58. 827. 5 to 36. 217. 0 g h/ml, P < 0. 05) concentrations, and postprandial endothelial dysfunction assessed by % FMD (maximum reduction in % FMD, from -2. 61. 1 % to -1. 20. 8 %, P < 0. 05), whereas no significant changes were observed in the control group.